COPD Cachexia: Deciphering the Impact of Antioxidants, Iron and Mitochondrial Function Using 'Omics Approaches

NIH RePORTER · NIH · R01 · $111,375 · view on reporter.nih.gov ↗

Abstract

SUMMARY Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death in the United States with mortality continuing to rise despite advances in medicine. Cachexia, a form of muscle wasting, is a debilitating co-morbidity whose prevalence increases with severity of COPD. But, cachexia still occurs among COPD patients with milder disease severity. Cachexia is most often thought of with respect to cancer. However, by population prevalence there are more COPD patients with cachexia than cancer patients with cachexia. Yet there have been few studies investigating the etiology of COPD cachexia underscoring the need for investigations of COPD cachexia and weight-loss. Accumulating data including our own points to a role for iron toxicity in the etiology of COPD cachexia. Heme is an essential component of mitochondrial cytochromes providing protection from reactive oxygen species (ROS). Defects in heme biosynthesis cause buildup of free iron, ROS and mitochondrial dysfunction. Buildup of free iron leads to iron toxicity and production of ROS particularly in the absence of adequate intake of antioxidants such as Vitamins E. As such, our overarching hypothesis is iron toxicity in COPD cachexia is driven by impaired antioxidant and mitochondrial function. This supplement will expand on Aim1 of the parent R01. 1) To determine whether genomic variation associated with the absorption and regulation of Vitamin E is more common in COPD cachexia we will perform analysis of whole- genome sequence data from subjects recruited from All of Us and participants in the Trans Omics for Precision Medicine (TOPMed) Initiative.

Key facts

NIH application ID
10659943
Project number
3R01HL153460-02S1
Recipient
UNIVERSITY OF ALABAMA AT BIRMINGHAM
Principal Investigator
Merry-Lynn Noelle McDonald Donnelly
Activity code
R01
Funding institute
NIH
Fiscal year
2022
Award amount
$111,375
Award type
3
Project period
2021-06-10 → 2025-05-31